NASDAQ:AKRX - Akorn Stock Price, Forecast & News

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) released its quarterly earnings results on Thursday, October, 31st. The company reported $0.02 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.06. The business had revenue of $176.24 million for the quarter, compared to the consensus estimate of $176.15 million. Akorn had a negative net margin of 53.62% and a negative return on equity of 19.95%. The company's quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the firm earned ($0.06) earnings per share. View Akorn's Earnings History.

4 equities research analysts have issued 1-year price objectives for Akorn's shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate Akorn's share price to reach $7.00 in the next year. This suggests a possible upside of 86.7% from the stock's current price. View Analyst Price Targets for Akorn.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.

News stories about AKRX stock have trended negative on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Akorn earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Akorn.

Akorn saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 7,650,000 shares, a drop of 17.6% from the September 30th total of 9,280,000 shares. Based on an average daily volume of 1,860,000 shares, the short-interest ratio is currently 4.1 days. Currently, 8.1% of the shares of the company are sold short. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn's stock is owned by a number of of retail and institutional investors. Top institutional investors include Millennium Management LLC (2.66%), State Street Corp (2.60%), Canyon Capital Advisors LLC (2.38%), Mackay Shields LLC (0.57%), Gabelli Funds LLC (0.35%) and Gamco Investors INC. ET AL (0.29%). Company insiders that own Akorn stock include Alan D Weinstein, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, State Street Corp, Assenagon Asset Management S.A., Barclays PLC, SG Americas Securities LLC, Chicago Equity Partners LLC and Gabelli Funds LLC. View Insider Buying and Selling for Akorn.

AKRX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Mackay Shields LLC, Canyon Capital Advisors LLC, Tibra Equities Europe Ltd, State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Gamco Investors INC. ET AL and California Public Employees Retirement System. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $3.75.

Akorn has a market capitalization of $473.05 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]